TransMedics Group, Inc. (TMDX)
Stock Price:
$17.42 USD
0.81 (4.88%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
472.28M |
| Revenue (ttm) |
26.46M |
| Net Income (ttm) |
-35.50M |
| Shares Out |
27.11M |
| EPS (ttm) |
-1.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$17.42 |
| Previous Close |
$16.61 |
| Change ($) |
0.81 |
| Change (%) |
4.88% |
| Day's Open |
16.91 |
| Day's Range |
16.70 - 17.72 |
| Day's Volume |
137,450 |
| 52-Week Range |
10.10 - 28.90 |
More Stats
| Market Cap |
472.28M |
| Enterprise Value |
433.50M |
| Earnings Date (est) |
Aug 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.11M |
| Float |
15.06M |
| EPS (basic) |
-1.82 |
| EPS (diluted) |
-1.85 |
| FCF / Share |
-1.59 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.08M |
| Short Ratio |
4.03 |
| Short % of Float |
8.40% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
17.85 |
| PB Ratio |
7.70 |
| Revenue |
26.46M |
| Operating Income |
-31.66M |
| Net Income |
-35.50M |
| Free Cash Flow |
-33.64M |
| Net Cash |
38.79M |
| Net Cash / Share |
1.43 |
| Gross Margin |
52.40% |
| Operating Margin |
-119.65% |
| Profit Margin |
-134.20% |
| FCF Margin |
-127.13% |
| ROA |
-29.17% |
| ROE |
-204.11% |
| ROIC |
-31.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.00*
(14.81% upside)
Low
15.0
Current: 17.42
High
25.0
Target: 20.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 23.60 | 13.02 | 7.69 | 6.21 |
| Revenue Growth | 81.33% | 69.38% | 23.77% | - |
| Gross Profit | 13.86 | 5.73 | 2.14 | 0.77 |
| Operating Income | -29.60 | -20.24 | -20.43 | -22.99 |
| Net Income | -33.55 | -23.76 | -20.82 | -24.07 |
| Shares Outstanding | 14.20 | 1.36 | 4.65 | 4.50 |
| Earnings Per Share | -2.36 | -17.48 | -4.48 | -5.35 |
| Operating Cash Flow | -32.29 | -25.98 | -23.10 | -24.11 |
| Capital Expenditures | -0.17 | -0.42 | -0.26 | -1.48 |
| Free Cash Flow | -32.45 | -26.40 | -23.36 | -25.59 |
| Cash & Equivalents | 81.19 | 20.74 | 25.16 | 0.00 |
| Total Debt | 34.15 | 33.67 | 8.65 | - |
| Net Cash / Debt | 47.04 | -12.93 | 16.51 | 0.00 |
| Assets | 105 | 42.16 | 37.00 | - |
| Liabilities | 50.65 | 47.88 | 19.21 | - |
| Book Value | 54.65 | -192 | -169 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
TransMedics Group, Inc. |
| Country |
United States |
| Employees |
109 |
| CEO |
Waleed H. Hassanein |
Stock Information
| Ticker Symbol |
TMDX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: TMDX |
Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion apparatus, optimization, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.